Primenenie olanzapina, obshchie i prakticheskie aspekty


Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

Olanzapine is a modern atypical antipsychotic drug, which is high effective in the treatment of productive and negative mental disorders, has no extrapyramidal side effects, and can suppress further progression of the disease. Due to a wide range of psychotropic activity and good tolerability, olanzapine is the drug of choice in the treatment of various mental disorders. Nevertheless, it is important to take into account a number of features of this drug. General practitioners can be faced with specific symptoms associated with the use of olanzapine; in this regard, they must have sufficient information for a correct interpretation of the various features of the patient’s state.

Толық мәтін

Рұқсат жабық

Авторлар туралы

A. Etingof

A. Magomedova

Email: annaetingof@yandex.ru

Әдебиет тізімі

  1. Гурович И.Я., Шмуклер А.Б., Магомедова М.В. и др. Первый психотический эпизод: особенности терапии оланзапином. Социальная и клиническая психиатрия. 2004; 14(2): 62-7.
  2. Гурович И.Я., Шмуклер А.Б., Магомедова М.В. и др. Динамика ремиссии у больных шизофренией и шизоаффективным расстройством после первых психотических приступов: длительная поддерживающая терапия оланзапином. Социальная и клиническая психиатрия. 2005; 15( 1 ): 53-6.
  3. Морозова М.А., Жаркова Н.Б., Бениашвили А.Г. Опыт применения атипичного нейролептика-оланзапина в остром периоде шизофрении. Журнал неврологии и психиатрии им. С.С. Корсакова. 2000; 4: 37-43.
  4. Мосолов С.Н. Шкалы психометрической оценки симптомов шизофрении и концепция позитивных и негативных расстройств. М., 2001. С. 135-200.
  5. Мосолов С.Н. и др. Сравнительная эффективность и переносимость длительного применения рисперидона, кветиапина, оланзапина и галоперидола у больных с впервые выявленной шизофренией. Социальная и клиническая психиатрия. 2007; 17(1).
  6. Baldwin D.S., Montgomery S.A. First Clinical Experience With Olanzapine (LY 170053): Results of an Open-Label Safety and Dose-Ranging Study in Patients With Schizophrenia, Int Clin. Psychopharmacol. 1995; 10(4): 239-44.
  7. Beasley C.M. Jr., Hamilton S.H., Crowford A.M., et al. Olanzapine Versus Haloperidol: acute phase results of the international double-blinde olanzapine trial. Eur. Neuropsychopharmacol. 1997; 7: 125.
  8. Barnes T.R. A rating scale for drug-induced akathisia. Br. J. Psychiatry. 1989; 154: 672-76.
  9. Bobes J., Rejas J., Garcia-Garcia M., et al. Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol: results of the EIRE study. Schizophr. Res. 2003; 62: 77.
  10. Brooks J.O. 3rd, Chang H.S., Krasnikh O. Metabolic risks in order adults receiving second-generation anti-psychotic medication. Curr. Psychianry Rep. 2009; 1. 1: 33.
  11. Callaghan J.T., Bergstrom R.T., Ptak L.R., Beasley C.M. Olanzapine. Pharmacokinetic and Pharmacodinamic profile. Clin. Pharmacokinet. 1999; 37(3): 177-93.
  12. Davis J.M., Chen N., Glick I.D. A Metaanalysis of the Efficacy of Second-Generation Antipsychotics, Arch. Gen. Psychiatry. 2003; 60(6): 553-64.
  13. Dixon L., Perkins D., Calmes C., Guideline Watch (September 2009): Practice Guideline for the Treatment of Schizophrenia. Arlington, Va: American Psychiatric Assotiation, 2009.
  14. Fontain C.S., Hynan L.S., Koch K., et al. A double-blind comparison of olanzapine versus risperidone in the acute treatment of dementia-related behavioral disturbances in extended care facilities. J. Clin. Psychiatry. 2003; 64: 726.
  15. Kinon B.J., Volavka J., Stauffer V., et al. Standard and Higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed-dose study. J. Clin. Psychopharmacol. 2008; 28: 392.
  16. Kreyenbuhl J., Buchanan R.W., Dickerson F.B., et al. The schizophrenia Patients Outcomes Research Team (PORT): Updated Treatment Recommendations 2009. Schizophr. Bull. 2010; 36: 94.
  17. Kryzhanovskaya J., Schulz S.C., McDougle C., et al. Olanzapine Versus Placebo in Adolescents with Schizophrenia: A 6-week, Randomized Double-Blind, Placebo-controlled Trial. J. Am. Acad. Adolesc. Psychiatry. 2009; 48( 1 ): 60-70.
  18. Lehman A.F., Lieberman J.A., Dixon L.B., et al. American Psychiatric Assosiation, Streeting Committee on Practice Guidelines. Practice guidelines for the treatment of patients with schizophrenia, Second Edition. Am. J. Psychiatry. 2004; 161(2 Suppl): 1-56.
  19. Lieberman J.A., Stroup T.S., McEvoy J.P., et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 2005; 353: 1209.
  20. McCue R.E., Waheed R., Urcuyo L., et al. Comparative effectiveness of second-generation antipsychotics and haloperidol in acute schizophrenia. Br. J. Psychiatry. 2006; 189: 433-40.
  21. Soutullo C.A., Sorter M.T., Foster K.D., et al. Olanzapine in the treatment of adolescent acute mania: A Report of Seven Cases. J. Affect. Disord. 1999: 53(3): 279-83.
  22. Tamayo J.M., Sutton V.K., Mattei M.A., et al. Effectiveness and safety of the combination of the fluoxetine and olanzapine in outpatients with bipolar depression: an open-label, randomized, flexible-dose study in Puerto Rico. J. Clin. Psychopharmacol. 2009; 29: 358.
  23. Tohen M., Vierta E., Calabrese J., et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch. Gen. Psychiatry. 2003; 60: 1079.
  24. Tran P.V., Dellva M.A., Tollefsan G.D., et al. Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia. J. Clin. Psychiatry. 1997; 58: 205.

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

© Bionika Media, 2014

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>